(potassium chloride extended-release tablets, USP)
K-TAB (potassium chloride extended-release tablets) is a solid oral dosage form of potassium chloride containing 750 mg of potassium chloride, USP, equivalent to 10 mEq of potassium in a film-coated (not enteric-coated), wax matrix tablet. This formulation is intended to slow the release of potassium so that the likelihood of a high localized concentration of potassium chloride within the gastrointestinal tract is reduced. The expended inert, porous, wax/polymer matrix is not absorbed and may be excreted intact in the stool.
BECAUSE OF REPORTS OF INTESTINAL AND GASTRIC ULCERATION AND BLEEDING WITH CONTROLLED-RELEASE POTASSIUM CHLORIDE PREPARATIONS, THESE DRUGS SHOULD BE RESERVED FOR THOSE PATIENTS WHO CANNOT TOLERATE OR REFUSE TO TAKE LIQUID OR EFFERVESCENT POTASSIUM PREPARATIONS, OR FOR PATIENTS WITH WHOM THERE IS A PROBLEM OF COMPLIANCE WITH THESE PREPARATIONS.
For the treatment of patients with hypokalemia with or without metabolic alkalosis, in digitalis intoxication, and in patients with hypokalemic familial periodic paralysis. If hypokalemia is the result of diuretic therapy, consideration should be given to the use of a lower dose of diuretic, which may be sufficient without leading to hypokalemia.
For the prevention of hypokalemia in patients who would be at particular risk if hypokalemia were to develop, e.g., digitalized patients or patients with significant cardiac arrhythmias.
The use of potassium salts in patients receiving diuretics for uncomplicated essential hypertension is often unnecessary when such patients have a normal dietary pattern, and when low doses of the diuretic are used. Serum potassium should be checked periodically, however, and, if hypokalemia occurs, dietary supplementation with potassium-containing foods may be adequate to control milder cases. In more severe cases and if dose adjustment of the diuretic is ineffective or unwarranted supplementation with potassium salts may be indicated.
Published Studies Related to K-TAB (Potassium Chloride)
A double-blind, randomized, parallel, placebo-controlled study examining the
effect of cross-linked polyelectrolyte in heart failure patients with chronic
kidney disease. 
CONCLUSION: In advanced, symptomatic HF with CKD, CLP is associated with
Efficacy of a commercial dentifrice containing 2% strontium chloride and 5%
potassium nitrate for dentin hypersensitivity: a 3-day clinical study in adults
in China. 
silica base without any active ingredient (control dentifrice)... CONCLUSION: In these patients with DH in China, the dentifrice containing 2%
One single dose of histidine-tryptophan-ketoglutarate solution gives equally good myocardial protection in elective mitral valve surgery as repetitive cold blood cardioplegia: a prospective randomized study. [2011.04]
OBJECTIVES: Histidine-tryptophan-ketoglutarate (HTK-Custodiol) cardioplegic solution is administered as one single dose for more than 2 hours of ischemia. No prospective randomized clinical study has compared the effects of HTK and cold blood cardioplegia on myocardial damage in elective mitral valve surgery. Thus, the main aim of the present study was to examine whether one single dose of cold antegrade HTK gives as good myocardial protection as repetitive antegrade cold blood cardioplegia in mitral valve surgery... CONCLUSIONS: One single dose of antegrade cold HTK cardioplegic solution in elective mitral valve surgery protects the myocardium equally well as repetitive antegrade cold blood cardioplegia. Copyright (c) 2011 The American Association for Thoracic Surgery. Published by Mosby, Inc. All rights reserved.
Improving outcome of treatment of kala-azar by supplementation of amphotericin B with physiologic saline and potassium chloride. [2010.11]
Complications of amphotericin B limit its wide application in the treatment of patients with kala-azar. This study was undertaken with an aim to minimize anti-renal complications and severe rigor in course of treatment with this drug... Supplementation of amphotericin B with 500 mL of physiologic saline and 30 mL (60 meq/L) of KCl during treatment could help prevent an increase in serum creatinine levels and severe rigor and would make the treatment of kala-azar with amphotericin B easier.
Push-out bond strength of mineral trioxide aggregate in the presence of alkaline pH. [2010.11]
INTRODUCTION: The aim of this study was to evaluate the effect of a range of alkaline pH values on the push-out strength of white mineral trioxide aggregate (WMTA)... CONCLUSIONS: Push-out bond strength of WMTA could be influenced by different alkaline pH values. Copyright (c) 2010 American Association of Endodontists. Published by Elsevier Inc. All rights reserved.
Clinical Trials Related to K-TAB (Potassium Chloride)
Comparison of Two Potassium Targets Within the Normal Range in Intensive Care Patients [Recruiting]
Rationale: It is well known that distinctly abnormal blood potassium values can cause
serious complications such as cardiac arrhythmias. Although potassium regulation is
generally considered important, hardly any research has been done about potassium regulation
in intensive care patients. The investigators hypothesize that different potassium
target-values, within the as normal accepted range, may have different effects in critically
Study design: A prospective trial comparing two different potassium target-values. Potassium
will be tightly regulated with the already fully operational GRIP-II computer program.
Study population: 1200 adult patients admitted at the thoracic intensive care unit of the
University Medical Center Groningen.
Intervention: Comparison between two variations of standard therapy: potassium target-value
of 4. 0 mmol/L versus 4. 5 mmol/L.
Main study parameters/endpoints: The primary endpoint is the incidence of atrial
fibrillation or atrial flutter from ICU-admission to hospital discharge. Secondary endpoints
are serum levels of potassium and the other main electrolytes, renal function and renal
potassium excretion, the relation with insulin and glucose, the cumulative fluid balance,
(ICU) length of stay and mortality.
Potassium Intake in Patients With Chronic Kidney Disease [Recruiting]
Chronic kidney disease is associated with high blood pressure, heart disease, and strokes.
Potassium lowers blood pressure and may help prevent heart disease and strokes in the
general population, but has not been well-studied in people with kidney disease. This study
will look at the benefits and safety of two levels of potassium intake in patients with
kidney disease. We expect that a higher level of potassium intake safely lowers blood
pressure compared to a lower level of potassium intake. We hope that this and other research
projects will help us to learn more so that guidelines can be created for potassium intake
in patients with chronic kidney disease
The Circadian Rhythm of Potassium and Cystatin C [Recruiting]
The potassium value is important to prevent cardiac arrhythmias and sudden cardiac death. In
patients with renal failure, the potassium value is not stable and tends to raise. Until now
there are no data available if the potassium value has a circadian rhythm and if there are
individual changes from day to day.
Effects of Potassium Citrate in Urine of Children With Elevated Calcium in Urine and Kidney Stones [Completed]
High amounts of calcium in the urine (hypercalciuria) can cause development of kidney stones
in children. Treatment for these children includes plenty of fluids, a low-salt diet and
medications such as potassium citrate. A major advantage of potassium citrate, as compared to
hydrochlorothiazide, is its lack of side effects. One problem the researchers and others
have observed is that some children continue to form kidney stones despite correction of
hypercalciuria with potassium citrate. One possible explanation is that in some individuals
potassium citrate therapy results in an excessive elevation of urine pH, a situation that may
predispose to calcium phosphate stone formation. In this study, the researchers will study
the effects of potassium citrate on urine chemistries and acid-base balance in three groups
of children aged 5-17 years:
- children who are hypercalciuric stone formers;
- healthy children without a history of hypercalciuria or kidney stones.
Particular attention will be paid to try to identify those who develop a very high urine pH
(>8) and the factors leading to this metabolic reaction.
The researchers will try to learn whether it is the child’s characteristics, the disease
manifestations, the dose of the drug, or a combination of the above which may be the cause of
the development of very alkaline urine. Based on the results, the researchers hope to be able
to better “tailor” the individual treatment for each child with kidney stones.
Potassium-Magnesium Citrate as a Blood Pressure Lowering Agent in Hypertensive Patients [Recruiting]
The goal of this study is to compare the effects of Potassium Magnesium Citrate to Potassium
Chloride on blood pressure among patients with pre-hypertension or mild hypertension. We
will also test whether Potassium Magnesium Citrate increases excretion of large amounts of
sodium in the urine.
Reports of Suspected K-TAB (Potassium Chloride) Side Effects
Medication Residue (2),
Tongue Discolouration (1),
Drug Ineffective (1),
Abdominal Pain Upper (1),
Faeces Discoloured (1), more >>